Since the observations of Freund (2) in 1885 of spontaneous hyperglycemia in patients with malignant disease, there has been speculation that an alteration in glucose metabolism is associated with neoplasia in man (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . There have been, however, relatively few studies designed specifically to test this possibility. Rohdenburg, Bernhard, and Krehbiel (5) and Edwards (6) , with the advent of the oral glucose tolerance test, reported that a decrease in carbohydrate tolerance was a uniform finding in patients with cancer.
Subsequent studies (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) did not confirm these reports, though several workers have found a high incidence of an abnormal glucose tolerance test in subjects with various types of neoplasms. These observations have been inconclusive with regard to establishing a relationship between the presence of uncomplicated neoplastic disease and an altered carbohydrate metabolism. A primary reason for the inconclusive nature of these studies is their lack of control of various factors known to decrease glucose tolerance. Certain of these factors, e.g., inadequate dietary intake, fever, infection, hepatic dysfunction and prolonged bed rest, are frequently present in patients with malignant disease.
This study was undertaken in a group of carefully selected patients with chronic leukemia, lymphoma, and clinically early epithelial neoplasms, and subjects without cancer, in an effort to determine whether a defect in glucose metabolism is associated with malignant tumors. It was found that, as a group, the patients with neoplastic dis-1 A portion of the present data has been published previously in abstract form (1) .
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ease had a significant decrease in the rate of disappearance of glucose from the blood following the intravenous injection of glucose. Carbohydrate metabolism was evaluated further in these subjects by calculation of the net rate of disappearance of glucose from the blood and the volume of distribution of glucose and by determination of the changes in serum inorganic phosphate and potassium concentrations during the glucose tolerance tests.
METHODS

Subjects studied
The control group consisted of 19 individuals without neoplastic disease, 7 males and 12 females, ranging in age from 29 to 65 years. The neoplastic group included 36 individuals., 14 males and 22 females, ranging in age from 36 to 70 years. There was no significant difference between the control and neoplastic groups with respect to age or body weight. Subjects 20 through 33 had clinically localized carcinoma, which was in all instances considered amenable to curative therapy. These individuals had no systemic symptoms. Carcinoma was suspected on the basis of a finding of a lump in the breast on physical examination, a positive Papanicoloau smear on routine cervical examination, or an abnormal shadow on routine chest x-ray. Subjects 34 through 54 had lymphoma or chronic leukemia. The diagnosis in each individual was established histologically (Tables I  and II ). All subjects were studied preoperatively, or prior to chemotherapy or radiotherapy.
The criteria for selection of individuals for study in both the control and patient group included: 1) no family history of diabetes mellitus, 2) full ambulation, 3) no weight change for at least six months prior to the study, 4) no obesity, 5) no evidence or history of any disorder known to affect carbohydrate metabolism, 6) no fever, -7) normal serum concentrations of sodium, potassium, chloride, carbon dioxide, non-protein nitrogen, alkaline phosphatase, cholesterol and cholesterol ester, and a normal cephalin flocculation, and 8) an adequate dietary intake. In control subjects, 1 through 11, and patients 20 through 27, and 34 through 42, twenty-five grams of glucose was administered from a syringe over a four-minute period. In all other individuals, the glucose was administered using a Bowman constant infusion pump over a three to five-minute period. This permitted a more accurate determination of the amount of glucose delivered (Table VI) .
Venous blood specimens were withdrawn without stasis into heparinized syringes at eight minutes following the start of the glucose injection and subsequently every eight minutes for 64 minutes. Glucose concentration and, when performed, serum inorganic phosphate and serum potassium concentrations were determined in duplicate on each blood sample. The blood specimens were immediately iced and protein-free filtrates for the glucose analyses were promptly prepared at the bedside. Urine was collected during the 75 minutes following the injection of glucose for the determination of urinary glucose excretion during the test.
Ten patients had 2 or 3 repeat glucose tolerance tests performed (Table III) . Six of these subjects were maintained on a constant carbohydrate and caloric intake on the metabolic ward during the interval between the studies. The remaining four individuals followed the prescribed diet on an outpatient basis during the period of observation.
Glucose was determined in duplicate by the Nelson modification of the Somogyi method (19, 20) . Serum inorganic phosphorus determinations were made according to the method of Taussky and Shorr (21) . Serum potassiums were determined using a flame photometer with an internal standard.
Analysis of glucose tolerance curves Methods of analysis of the rapid intravenous glucose tolerance test have varied. In the present study, each glucose tolerance curve was graphically evaluated both by the method suggested by Conard, Franckson, Bastenie, Kestens, and Kovacs (22) and by the technique employed by Amatuzio, Stutzman, Vanderbilt, and Nesbitt (23) . These two methods were chosen because (a) they provide methods which facilitate analyzing the glucose tolerance curve in terms of a single constant, (b) a large amount of normal data is available in the literature for these techniques, and (c) in the present study, by means of statistical analyses which will be presented below, they were found to provide good reproducibility in a given individual, and good discrimination between the control and neoplastic groups.
The intravenous glucose tolerance curve may be analyzed by plotting the log of the total blood glucose concentration against time to obtain a straight line (22) . This relationship suggests that the rate of fall of blood glucose at any time is proportional to the total blood glucose value at that time.
Amatuzio and his co-workers (23) found that the plot of the log of the blood glucose value in excess of the initial fasting level against time was a straight line. These authors suggested, therefore, that the rate of fall of blood glucose at any time is proportional to the blood glucose concentration in excess of the fasting level at that time.
An index of glucose tolerance may be obtained by plotting the data according to either of the above indicated methods and then applying the equation:
where in determining the fractional rate constant of disappearance of "total glucose" (Kb), ti,. is the time in minutes required for the total blood sugar value at any point to decline 50 per cent, or, in determining the fractional rate constant of disappearance of "increment glucose" (K.), tip is the time in minutes required for the blood sugar value in excess of the fasting level at any point to decline 50 per cent.
Analysis of the present data, in accord with previously published studies (24, 25) , indicates that neither of the methods (22, 23) (Table IV) (Table V) . Furthermore, the discrimination between the neoplastic and normal group was equally good whether Kb or K. was employed in analysis of the data (Table V) . the blood. In order to obtain the mean net rate of disappearance of "total glucose" from the blood per minute (G.D.b), the average "total glucose" concentration was multiplied by the rate constant Kb. The mean net rate of disappearance of "increment glucose" from the blood (G.D..) was derived by multiplying K. by the mean glucose concentration in excess of the fasting level.5 All values for net rate of disappearance of glucose, in subjects receiving other than 25 gm. of glucose, were corrected to this dose. The value obtained for mean net rate of disappearance of glucose is 5The value for the average "total glucose" concentration was obtained by the equation:
where Gb is the average "total glucose" concentration in mgm. per 100 cc.; Go is the total blood glucose concentration in mgm. per 100 cc. at zero time; t is the time interval in minutes during which the fractional rate of "total glucose" disappearance is constant.
The value for the average "increment glucose" concentration was obtained by the equation:
-(Go-Gf) (1 e-Kat)
tK.
where G. is the average "increment glucose" concentration in mgm. per 100 cc.; Gf is the fasting blood glucose concentration in mgm. per 100 cc.; t is the time interval in minutes during which the fractional rate of "increment glucose" disappearance is constant.
defined by the method employed in its calculation. It is used in this study only for the purpose of comparing the control and neoplastic groups with respect to this parameter. The value for G.D.b would be expected to be equal to the value for G.D.. if both a plot of the log of the "total glucose" concentration against time and a plot of the log of the "increment glucose" concentration against time represent good approximations of a straight line.
Estimation of volume of distribution of glucose. An estimate of the volume of distribution of glucose (EVG) was obtained in those subjects in whom the glucose was given using a constant infusion pump to permit an accurate determination of the volume of glucose solution injected. The EVG was calculated by dividing the amount of glucose injected (mgm.) by the glucose concentration in excess of the fasting value (mgm. per 100 cc.) at the end of injection. This glucose concentration was determined by extrapolating to the end of the injection period the linear plot of the log of the glucose concentration in excess of the fasting level between 16 and 56 minutes following the injections. The values for blood sugar concentration prior to 16 minutes generally fell above this line and were not employed in this graphic analysis to reduce the error due to mixing. It is recognized that this calculation is not free from objection, particularly when applied to metabolizable substances. Nevertheless, it is assumed that these errors will be similar in both control and neoplastic subjects.
RESULTS
The data obtained from intravenous glucose tolerance tests in 19 control subjects and 36 patients with neoplastic diseases are presented in Tables I and II . The diagnosis of each subject is indicated in these tables.
Fractional rate constant of glucose disappearance
The fractional rate of "total glucose" disappearance (Kb) for the control group was 1.97 ± 
Blood sugar values
The fasting blood sugar for the control series was 83 ± 8 mgm. per cent and for the neoplastic group 89 + 13 mgm. per cent (Tables I and II) . The difference between these means was not statistically significant. Four patients with neoplastic disease did have fasting blood sugars in excess of 100 mgm. per cent, which was the upper value for the range of fasting blood sugar levels in the control group.
The average blood sugar values for the control and neoplastic groups at 8 and 16 minutes following glucose administration were not significantly different. The mean blood sugar concentrations at subsequent sampling times, i.e., 24, 32, 40, 56 and 64 minutes, following glucose administration were significantly higher in the patients with neoplastic disease than in the control individuals (Tables I and II) .
Urinary glucose excretion during the 75 minutes following the intravenous administration of glucose was determined in 14 control individuals and 22 patients. Urinary glucose excretion amounted to 0.8 ± 0.3 gm. during the 75-minute period in control individuals and 0.6 + 0.3 gm. during the 75-minute period in the neoplastic group. There was no significant difference between these means.
Net rate of disappearance of glucose
The mean "total glucose" concentration (Gb) was 180 ± 29 mgm. per cent in the control individuals and 209 ± 40 mgm. per cent in the neoplastic group. In the control group, the net rate of disappearance of "total glucose" from the blood (G.D.b) was DISCUSSION A decrease in glucose tolerance, as indicated by a slower fractional rate of disappearance of blood glucose, was found to be associated with the presence of malignant disease. The fasting blood sugar was within the normal range in these subjects. The group of patients studied included individuals with lymphoma, chronic leukemia, and clinically localized carcinoma of the cervix, and carcinoma of the breast. These individuals were carefully selected to exclude various other factors known to impair carbohydrate metabolism.
The slower fractional rate of disappearance of glucose in the patients with malignant disease was associated with a higher mean blood sugar concentration following the intravenous administration of glucose. The question arises, in view of these findings, as to whether the net amount of glucose disappearing from the blood in the neoplastic group differed from the control subjects. The mean value for the net rate of disappearance of glucose was significantly lower in the patients compared with the control group. However, in the patient group, a normal net rate of disappearance of glucose was more frequently observed than a normal fractional rate of disappearance of glucose. There was no difference in the estimated volume of distribution of glucose between the patients and the control individuals. These calculated values derived from the disappearance curve of glucose indicate that in certain neoplastic subjects, despite a decreased fractional rate of disappearance of glucose, the persistence of blood glucose concentrations at significantly higher levels than in normal subjects may be associated with an approximately normal net rate of disappearance of glucose. A possible explanation of these findings is that net hepatic glucose output during the hyperglycemic phase is greater in the patients than in the control individuals and contributes to maintaiding the higher blood glucose concentration. This explanation does not exclude a concomitant decrease in tissue glucose utilization in these patients.
The present data do not permit conclusions as to the mechanism of the decrease in glucose tolerance. A slower fractional rate of disappearance of glucose, whether or not associated with a decreased net rate of disappearance of glucose, might result from an alteration in hepatic glucose metabolism, a decrease in peripheral utilization, or a disturbance in both of these metabolic processes.
Peripheral glucose utilization has been found to be associated with a fall in serum inorganic phosphate following glucose administration (33, 34) . A decrease in serum potassium concentration has also been reported to parallel glucose utilization (35) . No statistically significant difference was observed between the control and patient groups with reference to the maximum fall in the absolute concentration of serum inorganic phosphate or serum potassium. The mean fasting serum inorganic phosphate concentration in the patients with malignant disease was higher than in the control subjects. The maximum fall in serum inorganic phosphate expressed as per cent of the fasting level was smaller in the patient group than in the control individuals. It should be noted that in the patients with malignant disease, the maximum decrease in serum inorganic phosphate concentration and in serum potassium concentration was found to be variable, and in any given individual the magnitude of fall of these two ions did not parallel each other. The meaning of these findings in terms of glucose metabolism is not apparent.
The fact that the decrease in glucose tolerance was associated with localized carcinoma, small in size relative to total body mass, would make it unlikely that, in these patients at least, the decreased rate of disappearance of glucose was attributable to the carbohydrate metabolism of the tumor. Indeed, Cori and Cori (36) demonstrated that tumor in vtivo had an increased rate of glycolysis. It would appear that the defect in glucose metabolism reflects alterations in host tissue metabolism associated with the presence of the neoplastic process. In experimental animals, there are several reports of defects in enzyme activity (37) , including enzymes involved in carbohydrate metabolism (38) , of tissues of the tumorbearing host.
There are many studies on the incidence of cancer in diabetes mellitus (39) . In general, these reports found that cancer occurs more frequently than expected in diabetics. The pertinence of this finding, if real, to the present data cannot be evaluated on the basis of available knowledge. The possibility does exist that the decrease in glucose tolerance in patients with malignant disease may reflect latent diabetes mellitus.
It should be emphasized that the defect in carbohydrate metabolism, as measured by the intravenous glucose tolerance test, is not at all specific. A decrease in glucose tolerance has been observed in a wide variety of conditions in addition to diabetes mellitus, such as endocrine disorders, hepatic disease, malnutrition, infectious diseases, neuropsychiatric disorders, renal disease and obesity. None of these conditions existed in the present group of patients with neoplastic disease. Thus, this defect in glucose metabolism can be considered of no diagnostic value; however, its definition may shed some light on the metabolic alterations associated with neoplasia, as well as other conditions in which a decreased glucose tolerance may be present. SUMMARY 1. Intravenous glucose tolerance tests were performed in 36 carefully selected patients with chronic leukemia, lymphoma, and clinically early epithelial neoplasms, and in 19 subjects without cancer.
2. In analyzing the glucose tolerance curves, plotting either the log of the total blood sugar concentration against time, or the log of the blood sugar concentration in excess of the fasting value against time, provided an equally good index of glucose tolerance.
3. The patients with malignant disease compared with the control subjects had a significantly decreased fractional rate of disappearance of glucose and a significantly lower net rate of disappearance of glucose.
4. The fasting blood sugar concentration of the control and neoplastic groups did not differ significantly.
5. No significant difference in the estimated volume distribution of glucose was found between the two groups.
6. In the patients with malignant disease, the fasting serum inorganic phosphate concentration was significantly greater and the maximum per cent fall in inorganic phosphate was significantly less than in the control individuals. No significant difference was observed in the fall in serum potassium concentration between the two groups.
